lazertinib

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

lazertinib
Sep 11, 2024, 16:13 | Insight
RYBREVANT plus LAZCLUZE versus osimertinib in EGFR-mutated advanced lung cancer
New longer-term data from the MARIPOSA study confirm superior outcomes of chemotherapy-free RYBREVANT plus LAZCLUZE regimen compared…
Sep 10, 2024, 13:45 | Societies
Rami Manochakian's key highlights from WCLC24
WCLC is a major international event focused on the latest advancements in lung cancer research,…
Sep 9, 2024, 09:55 | Societies
Insights from WCLC24 by Chul Kim
The WCLC24 is taking place at the San Diego Convention Center from September 7 to…
Aug 29, 2024, 17:43 | Insight
FDA’s latest approvals summarized by Samuel Hume
Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…
Aug 24, 2024, 11:47 | Insight
Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial
Narjust Florez shared a post by IASLC on X, adding: “At The International Association for…
Aug 24, 2024, 11:15 | Insight
Jill Feldman: Exciting news for the EGFR lung cancer community
Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…
Aug 23, 2024, 14:21 | Drugs
Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?
Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…
Aug 22, 2024, 14:00 | Insight
Jarushka Naidoo: Phase II Lazertinib in EGFR+ NSCLC with CNS disease
Jarushka Naidoo shared a post on X: “Phase II Lazertinib in EGFR+ NSCLC with CNS disease,…
Aug 21, 2024, 17:08 | Insight
What oncologists say about the new approval of Lazertinib and amivantamab for advanced NSCLC
On August 19, 2024, the FDA approved a new combination therapy for advanced non-small cell…
Jul 19, 2024, 22:55 | Blog
What after Osimertinib failure?
Abhishek Pathak, Professor at the Indian Army, shared a post on X: "What after Osimertinib…
Jul 1, 2024, 15:01 | Blog
Antonio Passaro: A significant milestone for the advancement and understanding of EGFR-mutated NSCLC
Antonio Passaro, shared a post on LinkedIn: "I am honored to have contributed, as investigator…
Jun 28, 2024, 11:08 | Insight
New Paper Alert! Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results
Amivantamab-Lazertinib Improves Outcomes in High-Risk EGFR-Mutant NSCLC Subgroups: MARIPOSA Study Results Authors: E. Felip, B.C.…
Jun 21, 2024, 10:50 | Blog
Out in JCO the groundbreaking results of the randomized phase 3 trial PALOMA-3 study
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "Out in…
Jun 13, 2024, 15:48 | Insight
Stephen Liu on a paper by Natasha Leighl, et al.
Stephen Liu recently shared a post on X: "PALOMA-3 results at Journal of Clinical Oncology…
Jun 2, 2024, 09:09 | Societies
15 Posts From ASCO24 Day 2 You Should Not Miss!
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is being held from May…
May 29, 2024, 12:03 | Insight
Eric Singhi: MARIPOSA a path forward to help us determine who benefits from 1L combination therapy?
Eric Singhi shared on X:  "MARIPOSA: Amivantamab + lazertinib v osimertinib in 1L EGFR+ mNSCLC:…
May 28, 2024, 08:21 | Blog
Antonio Passaro's top 10 selection with explanation, among the lung cancer abstracts from ASCO24
Antonio Passaro, shared a post on X: ''ASCO24 is ready to start soon! Here, my top…
May 27, 2024, 04:19 | Opinion
Gilberto Lopes: My top ASCO24 lung cancer abstracts!
Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared…
Oct 29, 2023, 03:16 | Drugs
Antonio Passaro: I was honored to present in Presidential, the primary results of the global randomized phase 3 study MARIPOSA-2
Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn: "ESMO23 is…
All: 19 Posts: 1 - 100
Special Coverage